Follow
Alan Christy Hunter
Alan Christy Hunter
Associate Professor in Pharmaceutics (Drug Delivery and Nanomedicine)
Verified email at lincoln.ac.uk
Title
Cited by
Cited by
Year
Long-circulating and target-specific nanoparticles: theory to practice
SM Moghimi, AC Hunter, JC Murray
Pharmacological reviews 53 (2), 283-318, 2001
47402001
Nanomedicine: current status and future prospects
SM Moghimi, AC Hunter, JC Murray
The FASEB journal 19 (3), 311-330, 2005
26742005
A two-stage poly (ethylenimine)-mediated cytotoxicity: implications for gene transfer/therapy
SM Moghimi, P Symonds, JC Murray, AC Hunter, G Debska, A Szewczyk
Molecular therapy 11 (6), 990-995, 2005
12552005
Factors controlling nanoparticle pharmacokinetics: an integrated analysis and perspective
SM Moghimi, AC Hunter, TL Andresen
Annual review of pharmacology and toxicology 52, 481-503, 2012
5862012
Molecular hurdles in polyfectin design and mechanistic background to polycation induced cytotoxicity
AC Hunter
Advanced drug delivery reviews 58 (14), 1523-1531, 2006
5262006
Poloxamers and poloxamines in nanoparticle engineering and experimental medicine
SM Moghimi, AC Hunter
Trends in biotechnology 18 (10), 412-420, 2000
5172000
Agricultural robotics: the future of robotic agriculture
T Duckett, S Pearson, S Blackmore, B Grieve, WH Chen, G Cielniak, ...
arXiv preprint arXiv:1806.06762, 2018
3132018
Distinct polymer architecture mediates switching of complement activation pathways at the nanosphere− serum interface: implications for stealth nanoparticle engineering
I Hamad, O Al-Hanbali, AC Hunter, KJ Rutt, TL Andresen, SM Moghimi
ACS nano 4 (11), 6629-6638, 2010
3042010
Poly (ethylene glycol) s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process
I Hamad, AC Hunter, J Szebeni, SM Moghimi
Molecular immunology 46 (2), 225-232, 2008
2892008
Material properties in complement activation
SM Moghimi, AJ Andersen, D Ahmadvand, PP Wibroe, TL Andresen, ...
Advanced drug delivery reviews 63 (12), 1000-1007, 2011
2772011
Polycation cytotoxicity: a delicate matter for nucleic acid therapy—focus on polyethylenimine
L Parhamifar, AK Larsen, AC Hunter, TL Andresen, SM Moghimi
Soft Matter 6 (17), 4001-4009, 2010
2502010
Recognition by macrophages and liver cells of opsonized phospholipid vesicles and phospholipid headgroups
SM Moghimi, AC Hunter
Pharmaceutical research 18, 1-8, 2001
1972001
Complement activation cascade triggered by PEG–PL engineered nanomedicines and carbon nanotubes: The challenges ahead
SM Moghimi, AJ Andersen, SH Hashemi, B Lettiero, D Ahmadvand, ...
Journal of controlled release 146 (2), 175-181, 2010
1892010
PEGylation of microspheres generates a heterogeneous population of particles with differential surface characteristics and biological performance
JK Gbadamosi, AC Hunter, SM Moghimi
FEBS letters 532 (3), 338-344, 2002
1892002
Bypassing adverse injection reactions to nanoparticles through shape modification and attachment to erythrocytes
PP Wibroe, AC Anselmo, PH Nilsson, A Sarode, V Gupta, R Urbanics, ...
Nature nanotechnology 12 (6), 589-594, 2017
1762017
Low and high molecular weight poly (l-lysine) s/poly (l-lysine)–DNA complexes initiate mitochondrial-mediated apoptosis differently
P Symonds, JC Murray, AC Hunter, G Debska, A Szewczyk, SM Moghimi
FEBS letters 579 (27), 6191-6198, 2005
1542005
Cationic carriers of genetic material and cell death: a mitochondrial tale
AC Hunter, SM Moghimi
Biochimica et Biophysica Acta (BBA)-Bioenergetics 1797 (6-7), 1203-1209, 2010
1532010
Causative factors behind poloxamer 188 (Pluronic F68, Flocor™)-induced complement activation in human sera: A protective role against poloxamer-mediated complement activation …
SM Moghimi, AC Hunter, CM Dadswell, S Savay, CR Alving, J Szebeni
Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1689 (2), 103-113, 2004
1522004
Polymeric particulate technologies for oral drug delivery and targeting: a pathophysiological perspective
AC Hunter, J Elsom, PP Wibroe, SM Moghimi
Maturitas 73 (1), 5-18, 2012
1492012
Complement activation by PEGylated single-walled carbon nanotubes is independent of C1q and alternative pathway turnover
I Hamad, AC Hunter, KJ Rutt, Z Liu, H Dai, SM Moghimi
Molecular immunology 45 (14), 3797-3803, 2008
1442008
The system can't perform the operation now. Try again later.
Articles 1–20